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Abstract
Human FTO gene variants are associated with body mass index and type 2 diabetes. Because the obesity-associated SNPs
are intronic, it is unclear whether changes in FTO expression or splicing are the cause of obesity or if regulatory elements
within intron 1 influence upstream or downstream genes. We tested the idea that FTO itself is involved in obesity. We show
that a dominant point mutation in the mouse Fto gene results in reduced fat mass, increased energy expenditure, and
unchanged physical activity. Exposure to a high-fat diet enhances lean mass and lowers fat mass relative to control mice.
Biochemical studies suggest the mutation occurs in a structurally novel domain and modifies FTO function, possibly by
altering its dimerisation state. Gene expression profiling revealed increased expression of some fat and carbohydrate
metabolism genes and an improved inflammatory profile in white adipose tissue of mutant mice. These data provide direct
functional evidence that FTO is a causal gene underlying obesity. Compared to the reported mouse FTO knockout, our
model more accurately reflects the effect of human FTO variants; we observe a heterozygous as well as homozygous
phenotype, a smaller difference in weight and adiposity, and our mice do not show perinatal lethality or an age-related
reduction in size and length. Our model suggests that a search for human coding mutations in FTO may be informative and
that inhibition of FTO activity is a possible target for the treatment of morbid obesity.
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Introduction
In genome-wide association studies (GWAS) for type 2 diabetes,
a single nucleotide polymorphism (SNP) within intron 1 of the fat
mass and obesity-associated (FTO) gene was found to be associated
with an increased risk of obesity [1,2]. Around 16% of the
Caucasian population is homozygous for the risk allele and has an
,1.67-fold increased risk of obesity, weighing ,3 kg more than
controls. The risk allele is not associated with fetal growth but
confers an increased risk of elevated body mass index (BMI) and
obesity [1] that manifests by the age of 7 and persists into
adulthood. These results have largely been confirmed in other
populations [2–7].
FTO is a 9-exon gene located on human chromosome 16 and
mouse chromosome 8. Sequence analyses suggested that FTO has
homology with the AlkB family of DNA repair enzymes.
Subsequent in vitro biochemical studies revealed FTO to be a
member of the Fe(II) and 2-oxoglutarate (2OG) dependent
oxygenase superfamily [8]. In metazoans these enzymes are
involved in diverse processes including oxygen sensing, DNA
repair, fatty acid metabolism and post-translational modifications
[9]. Recombinant FTO catalyses oxidative demethylation of 3-
methylthymine and 3-methyluracil in single-stranded DNA and
RNA [8,10], suggesting its physiological role involves nucleic acid
modification. In vitro expression of murine FTO results in
localisation of the recombinant protein to the nucleus, consistent
with a role in nucleic acid modification [8].
FTO is ubiquitously expressed. In the brain, mRNA levels are
particularly high within the hippocampus, cerebellum and
hypothalamus [8,11]. In the hypothalamus, strong expression is
seen in the arcuate, paraventricular, dorsomedial and ventrome-
dial nuclei - sites critical for regulating energy balance [12].
The hypothalamic expression of FTO suggests a potential role in
the control of food intake and whole body metabolism. Consistent
with this idea, several studies have reported higher levels of energy
intake in individuals with the at-risk FTO allele [13–19]. Although
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expenditure measured by calorimetry in adults [16,20] or food
intake [21], the balance of evidence from population-based studies
suggests that FTO intron 1 SNPs are associated with increased
energy intake.
GWAS are a powerful way of identifying genes involved in
commondisease butitisoftendifficulttotranslate theirfindings into
an understanding of how the gene products act at the cellular and
whole animal levels. This is a particular problem when the disease-
associated SNP lies within an intron, as is the case for FTO. One
approach to identifying the function of a gene is to mutate it in a
model organism. A mouse possessing a 1.6 Mbp deletion in mouse
chromosome 8 that includes Fto as well as Ftm, Ft1, Irx3, Irx5 and
Irx6 has been characterised (fused toes or Ft mice) [22]. Homozygous
Ft mice are embryonic lethal and display neural tube defects, left-
right asymmetry and polydactyly. Heterozygous micehave fusion of
the forelimb digits and thymic hyperplasia [23]. Recently, a mouse
FTO knockout has been described in which exons 2 and 3 of Fto are
replaced by a neomycin STOP cassette [24]. This cassette also
deletes part of intron 1 although not the position equivalent to the
BMI-associated SNPs in human FTO. Homozygous FTO knockout
mice were viable but showed significant postnatal death before 4
weeks of age. They also exhibited postnatal growth retardation, a
reduction in adipose tissue, a reduction in lean mass, increased
energy expenditure, increased sympathetic nervous system activity,
relative hyperphagia and reduced spontaneous locomotor activity.
Thus this study suggested that Fto is directly involved in energy
metabolism and body weight regulation.
However, many human SNPs are likely to result in impaired
function rather than total loss of function, and mouse knockouts
are not always the most informative because they can result in a
non-viable or severely compromised organism. Indeed, knockout
of the mouse Fto gene is associated with increased postnatal death
and growth retardation [24], which is not observed for human
FTO variants. We therefore searched the Harwell mouse N-ethyl-
N-nitrosourea (ENU) archive for an Fto mutation that produces a
partial loss of function.
We describe here a dominant missense mutation (I367F) in the
mouse Fto gene that results in a lean phenotype of reduced body
weight and fat mass. Physical activity and food intake is unchanged
but metabolic rate is increased. We show by gene expression
analysis that fat and carbohydrate metabolism are increased in
mutant mice and they possess an improved inflammatory profile.
On a high-fat diet mutant mice show a lower fat mass than wild-
type mice. These results indicate that our mice provide an
improved model for the human phenotype and provide functional
evidence that the FTO gene is a causal gene underlying obesity.
Results
A Missense Mutation within the C-terminal Domain of
FTO
In a screen of DNA from 6,624 mice from the Harwell ENU-
induced mutagenesis archive [25] we identified an adenosine-to-
thymidine mutation in exon 6 of Fto leading to substitution of a
phenylalanine for isoleucine-367 (Fto
I367F) in the C-terminal region
of murine FTO (mFTO) (Figure 1A). Although this substitution
lies outside the predicted double-stranded b-helix (DSBH) and
associated elements that form the conserved ‘‘catalytic core’’ of
2OG oxygenases [9], the block of ,20 amino acids surrounding
I367 is conserved in FTO throughout vertebrate evolution
(Figure 1B), suggesting this region has a physiological role.
The C-terminal regions of some 2OG oxygenases are known to
facilitate oligomerisation [9,26]. We therefore compared expres-
sion of full-length and C-terminal truncated (residues 1–408, 1–
387 and 1–329 inclusive) mFTO in Escherichia coli. Although wild-
type mFTO was efficiently produced in a soluble form, C-
terminally truncated forms of wild-type mFTO and full-length
mFTO
I367F gave only low amounts of largely insoluble protein
(data not shown). By contrast, a His-tagged version of the C-
terminal domain alone (residues D329-end) of wild-type mFTO
(CmFTO) was efficiently produced in soluble form, CmFTO
I367F
was largely insoluble. Mutation of residue I367 to alanine (I367A),
however, yielded soluble mFTO
I367A and CmFTO
I367A proteins.
The catalytic activity of mFTO
I367A in the presence of a 3-
methylthymine containing oligonucleotide substrate, as measured
by 2OG turnover, was only ,40% of wild-type mFTO (Figure 2A).
As anticipated, because they lack the DSBH core, neither
CmFTO nor CmFTO
I367A were catalytically active (Figure 2A).
We analysed the oligomerisation states of mFTO and human
FTO (hFTO) by non-denaturing mass spectrometry (MS,
Figure 2B) and found that mFTO, hFTO and CmFTO exist as
a mixture of monomeric and dimeric forms (Figure S1 and Figure
S2). However, the proportion of dimeric mFTO
I367A is signifi-
cantly reduced relative to that in the wild-type mFTO (Figure S3).
We also investigated the oligomerisation state of the proteins in
solution using gel filtration chromatography (Figure 2C). This
revealed that whereas wild-type mFTO and CmFTO exist in both
monomeric and dimeric forms, both I367A variants exist, at least
predominantly, as monomers. These results suggest that I367 is
involved in dimerisation of FTO (Figure 2C). It was not possible to
analyse mFTO
I367F or CmFTO
I367F because of their insoluble
nature.
The secondary structure of the C-terminal domain was then
investigated using circular dichroism spectroscopy (Figure 2D). In
contrast to the full-length proteins, which contain the DSBH
‘‘core’’ domain of the 2OG oxygenases (comprising 8 b-strands
with surrounding loops and a-helices), the C-terminal domain
proteins are predominantly a-helical (Figure S4 and Figure S5). A
similar structural difference was observed for hFTO and its C-
terminal domain (residues 332-end; ChFTO, Figure S6). The
I367A mutation does not appear to alter the overall secondary
structure fold of mFTO proteins (Figure 2D), despite preventing
Author Summary
Geneticists have identified many gene regions that cause
human disease by using multiple genetic markers in large
populations to find gene regions associated with disease.
However, it is often not clear precisely which gene in any
given region causes the disease or how the gene exerts its
functional effect. For example, a gene variant in the non-
coding region of FTO enhances obesity risk, but it is not
clear if this is an effect of the FTO gene itself or another
gene located nearby. We therefore tested whether FTO
regulates body weight in the mouse. We found that a
single change (mutation) in the sequence coding for the
mouse FTO protein decreases the functional activity of FTO
and causes reduced fat mass and body weight. Food
intake and activity were normal, but the mutant mice had
a higher metabolic rate. In addition, their fat mass was
lower than that of normal mice when both were fed a
high-fat diet. Our study provides direct evidence that FTO
directly affects fat mass and thus is likely to have a role in
human obesity. As reduced FTO function decreases body
weight in mice, it is worth exploring if pharmaceutical
agents that inhibit FTO activity might help reduce human
obesity.
A Mutation in FTO Causes a Lean Phenotype
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folded, but that isoleucine 367 is involved in dimer formation.
Factor Inhibiting Hypoxia Inducible Factor (FIH), a human 2OG-
oxygenase involved in the hypoxic response, also exists as a dimer
[26]. For FIH, dimerisation is enabled by a C-terminal region.
However, sequence comparisons, coupled with structural predic-
tions, suggest that the C-terminal region of FTO and FIH will be
substantially different, with that of FTO having a more a-helical
character.
Overall, these results reveal that FTO can exist in both
monomeric and dimeric forms and that the C-terminal domain is
involved in dimerisation. The evidence suggests that the I367A
(and presumably I367F) mutation disrupts dimerisation and results
in a reduction of catalytic activity. In addition to the presumed
lower activity of mFTO
I367F, we cannot exclude the possibility that
a reduced stability of mFTO
I367F, leading to aggregation and/or
proteolytic degradation, contributes to the phenotype.
The Mutant FTO Protein Is Localised to the Nucleus and
Expressed at Lower Levels in Mammalian Cells
To establish if mFTO
I367F is stable in mammalian cells we
transfected Cos-7 and PC12 cell lines with a plasmid encoding Fto
or Fto
I367F N-terminally tagged with yellow florescent protein
(YFP), or with YFP alone. Imaging revealed that like mFTO [8],
mFTO
I367F localised to the nucleus (Figure 3A and data not
shown). However, fewer YFP-positive cells were observed than
when mFTO was transfected, suggesting mFTO
I367F is expressed
at lower levels. This was confirmed by immunoblotting of lysates
from cells expressing HA-tagged wild-type or mutant FTO
(Figure 3B). Similarly, immunoblotting of heterozygous and
homozygous Fto
I367F mouse brain and liver with an FTO antibody
confirmed that the mutant protein is expressed at lower levels than
wild-type (Figure 3C). These data therefore suggest that the I367F
mutation results in reduced FTO protein levels and thus is likely to
impair FTO function. However, it does not produce a total
knockout as some mFTO
I367F protein appears to be expressed and
correctly targeted to the nucleus.
Fto
I367F Mice Are Lean
In order to determine if the mutation affects body mass, mice
were weighed and measured weekly from 3 to 24 weeks. Both
homozygous and heterozygous male mice carrying the dominant
Fto
I367F mutation exhibited a maturity-onset reduction in body
weight (Figure 4A) diverging from wild-type at 12 weeks of age
(P=0.01) and becoming ,10% less than wild-type by 24 weeks.
There was no significant difference in body weight between
heterozygous and homozygous male mice. No difference was
observed between wild-type and mutant female mice (Table S1),
and all further experiments described were therefore confined to
male mice.
Dual Energy X-ray absorptiometry (DEXA) analysis revealed a
16–18% reduction in total fat mass between 24-week old Fto
I367F
Figure 1. An ENU-induced missense mutation I367F in exon 6 of FTO. (A) Sequencing reveals an A to T mutation in exon 6 of FTO that leads
to conversion of the isoleucine at residue 367 to phenylalanine. (B) Sequence line-up showing isoleucine 367 (arrow) and surrounding residues are
highly conserved in vertebrates. Colour code for amino acids indicates a consensus residue derived from a block of similar residues (black), a
completely conserved residue (red), a residue weakly similar to a consensus residue (orange), a consensus residue derived from the occurrence of
greater than 50% of a single residue (blue) and non-similar residues (dark-red).
doi:10.1371/journal.pgen.1000599.g001
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I367F mutation is within a C-terminal domain. (A) mFTO
I367A (light blue) shows reduced catalytic activity in a 2OG turnover
assay with a 3-meT oligonucleotide substrate, compared to mFTO (dark blue). Neither CmFTO (purple) nor CmFTO
I367A (grey) show significant 2OG
turnover. Data are expressed as mean6SEM. (B) Non-denaturing electrospray ionisation mass spectrometry analyses showing the dimeric nature of (i)
The C-terminal domain of mFTO (CmFTO), (ii) Full-length mFTO and (iii) Full-length human FTO. The twin peaks present in the CmFTO sample likely
result from a-N-gluconylation of the protein resulting in partial formation of a+178Da adduct (see Figure S1 and Figure S2). (C) Analytical gel filtration
chromatogram showing the presence of two FTO species in solution. (i) mFTO (red) and mFTO
I367A (blue), (ii) CmFTO (red) and CmFTO
I367A (blue). (D)
Circular dichroism spectra showing the secondary structures of mFTO (red), mFTO
I367A (blue), CmFTO (green) and CmFTO
I367A (black) at 0.25 mg/ml,
4uC.
doi:10.1371/journal.pgen.1000599.g002
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I367F protein is expressed at lower levels and localised in the nucleus. (A) Confocal fluorescence images of COS-7 cells
expressing YFP, YFP-FTO and YFP-FTO
I367F, as indicated. First column: YFP fluorescence. Second column: fluorescence from 49,6-diamidino-2-
phenylindole (DAPI), which stains nuclei. Third column: merged channels. (B) Western blot of protein from Cos cells expressing HA-FTO or HA-
FTOI367F, as indicated, probed with an anti-HA antibody. Below, loading control of the same gel probed with an anti-TATA-binding protein (TBP)
antibody. (C) Western blot of protein from liver and brain of wild-type (I/I), heterozygous (I/F) and homozygous (F/F) mice probed with a polyclonal
rabbit anti-FTO antibody. Below, loading control of the same gel probed with an anti-actin antibody.
doi:10.1371/journal.pgen.1000599.g003
A Mutation in FTO Causes a Lean Phenotype
PLoS Genetics | www.plosgenetics.org 5 August 2009 | Volume 5 | Issue 8 | e1000599and wild-type mice (Figure 4B). The proportion of body mass in
fat was reduced by ,4–7% from 36.4% fat in wild-type to 30.8–
32.9% fat in mutant mice. No significant difference in lean body
mass was observed (Figure 4C). This suggests that the lower weight
of the mutant mice is largely attributable to a decrease in fat mass.
Measurement of 24-hour cumulative food intake revealed no
statistically significant difference between control and Fto
I367F mice
on a normal chow diet at either 10 or 20 weeks, even after
normalisation for body weight (Figure 4D).
Mice Carrying the Fto
I367F Mutation Have a Higher
Metabolic Rate
To investigate the mechanism underlying the reduced body
weight, we measured O2 consumption, CO2 production and
respiratory exchange ratio (RER) at 18 weeks of age. Heterozy-
gous and homozygous Fto
I367F mice showed an increase in O2
consumption (Figure 5A) and CO2 production (Figure 5B) during
both the light and dark phase of activity. As a consequence, RER
was increased (Figure 5C). These data indicate the Fto
I367F
mutation causes an increase in whole body metabolism and a
switch to relatively more carbohydrate metabolism. There was no
difference in physical activity between wild-type and Fto
I367F mice,
as assessed by threshold crossing (Figure 5D), during either the
light and dark periods of a 22-hour measurement period.
Fto
I367F Mice Show an Altered Leptin-Adipose Mass Set-
Point and Increased Fasted Glucagon at 24 Weeks
An intraperitoneal glucose tolerance test (IPGTT) at 12 and 16
weeks of age did not reveal a significant difference between Fto
I367F
and wild-type mice (Text S1 and Figure S7A, S7B). Fasted serum
leptin levels were also not significantly different at 24 weeks (Figure
S7C). When circulating leptin levels were plotted against the
percentage of body fat we found (as expected) a positive
correlation for both heterozygous and homozygous Fto
I367F mice
(r 0.56, r
2 0.31, P=0.0295 and r 0.54, r
2 0.30, P=0.0238,
respectively). However, circulating leptin as a function of
Figure 4. Male Fto
I367F mice exhibit reduced body and fat mass. (A) Body weights of male heterozygous (I/F; n=21) and homozygous (F/F;
n=28) Fto
I367F mice and of wild-type littermates (I/I; n=15). (B,C) Fat mass (B) and lean body mass (C) of 24-week old male heterozygous (n=26),
homozygous (n=15) and wild-type (n=12) mice. (D) Food intake over 24 hours normalised to body weight (BW) measured at 10 weeks (I/I, n=20; I/
F, n=30; F/F, n=15) and 20 weeks (I/I, n=12; I/F, n=20; F/F, n=15). Data are expressed as mean6SEM, Statistical analysis was performed using
Student’s t-test. *, P,0.05; **, P,0.01 for differences between Fto
I367F heterozygous or homozygous mice and wild-type littermates.
doi:10.1371/journal.pgen.1000599.g004
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I367F mice exhibit enhanced metabolism. (A,B) Oxygen Consumption (A i) and carbon dioxide production (B i) over a 22-hr period
for 18-week old male heterozygous (I/F; n=30) and homozygous (F/F; n=15) Fto
I367F mice and wild-type littermates (I/I; n=26). Inset, total oxygen
consumption (A ii), and carbon dioxide production (B ii) over 22-hr. (C) Respiratory exchange ratio (RER) calculated from data given in A, B during the
light and dark period. (D) Physical activity over 23-hr for 18-week old male heterozygous (n=10), homozygous (n=11) and wild-type (n=7)
littermates. (E) Glucagon, glucose and lipid serum levels (as indicated) measured after overnight fasting at 24-weeks of age. WT (I/I; n=12),
heterozygous (I/F; n=17), and homozygous (F/F; n=15) littermates. Data are expressed as mean6SEM. *, P,0.05; **, P,0.01; ***, P,0.001 (Student’s
t-test) for differences between Fto
I367F and wild-type mice.
doi:10.1371/journal.pgen.1000599.g005
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comparison to controls suggesting higher leptin secretion per unit
of body fat (Figure S7D). Levels of fasting serum glucagon,
triglycerides, cholesterol and HDL were increased in 24-week old
Fto
I367F homozygous mice (Figure 5E). Fasting serum glucose was
also increased at 24 weeks (Figure 5E) but not at 12 or 16 weeks of
age (Figure S7A, S7B). No significant difference was observed in
serum insulin or adiponectin (Figure S7E, S7F). A 6-hour cold
challenge at 22 weeks did not reveal a significant difference
between genotypes (data not shown) suggesting that thermoregu-
lation by brown adipose tissue (BAT) is unaltered.
Fto
I367F Mice Have Altered Catecholamines and b-3
Adrenoreceptor Expression
Urinary catecholamines were analysed at 10 and 20 weeks of
age and normalised to urinary creatinine to control for volume.
Ten-week old homozygous Fto
I367F mice showed significantly
higher norepinephrine (Figure 6A) and dopamine (Figure 6B), but
no difference in epinephrine (Figure 6C), compared to wild-type
mice. However, only dopamine was elevated in 20-week old
homozygous Fto
I367F mice (P,0.05).
Sympathetic stimulation of white adipose tissue (WAT), brown
adipose tissue (BAT) and muscle increases metabolism by
stimulating lipolysis and thermogenesis. Expression of b-3
adrenoreceptor mRNA was increased in muscle and WAT, but
not BAT, of 16-week old homozygous Fto
I367F mice as measured
by quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR) (Figure 6D–6F). Expression of uncoupling protein 2
(Ucp2), and the catecholamine degradation enzyme catechol-O-
methyl transferase (Comt) were also upregulated in muscle of
homozygous Fto
I367F (Figure 6D).
Fto
I367F Mice Have Reduced Fat Mass and Increased Lean
Mass on a High-Fat Diet
Analysis of 24-week-old mice given a high-fat diet from weaning
revealed a significant reduction in fat mass and increased lean tissue
mass in Fto
I367F mice compared with wild-type mice (Figure S8A,
S8B, S8C). There was no difference in food intake between genotypes
at 10 and 20 weeks (Figure S8D). Fasting serum glucagon, glucose,
triglycerides, and HDL-C levels were all increased in Fto
I367F
homozygous mice whereas insulin levels were significantly lower
(Figure S8E, S8F, S8G, S8H). Fasted serum leptin levels were
significantly increased at 8 weeks in Fto
I367F m i c eb u tn o ta t2 4w e e k s .
A high-fat diet significantly increased oxygen consumption in
both wild-type and mutant mice (Figure S8I, S8J, S8K, S8L,
S8M), whereas carbon dioxide production increased in wild-type
but not Fto
I367F mice (Figure S8J, S8M). Interestingly, we did not
observe significant differences in either oxygen consumption or
carbon dioxide output between mutant and wild-type littermates
on a high-fat diet (in contrast to a normal diet). The RER of all
mice was significantly reduced on a high-fat diet, reflecting an
increase in relative fat metabolism. In the dark phase (when mice
are active) Fto
I367F mice maintained a significantly higher RER
than wild-type mice (Figure S8K).
Gene Expression Analysis in Fto
I367F Mutants
To determine if gene expression was altered in Fto
I367F mice we
carried out microarray analysis of WAT, liver and skeletal muscle
from 16-week old wild-type, heterozygous and homozygous
Fto
I367F mice. The genes that changed in heterozygous mice were
largely a subpopulation of those seen to change in homozygous
mice: thus we focus here on differences between homozygous and
wild-type animals. Significant gene expression changes were found
in all tissues, but very few were present in more than one tissue.
Only 9 genes were found to change in all three tissues, 11 were
common to muscle and liver, 24 to liver and WAT, and 31 to
muscle and WAT (Figure 7A). Few of these changes were
obviously related to the lean phenotype.
Multiple genes involved in inflammation were markedly down-
regulated in abdominal WAT (Figure 7B and Table S2). These
include the phospholipase A2 Pla2g7 (6.2-fold), the leukocyte
immunoglobulin-like receptor Lilrb4 (4.7-fold), the Integrin beta 2
Itgb2 (4.3fold), the macrophage scavenger receptor 1 Msr1 (3.6
fold), and very many more. A reduction in expression of genes
involved in the inflammatory response is consistent with the lean
phenotype of the Fto
I367F mice as adipose tissue normally contains
resident macrophages [27,28,29]. The array results were in good
agreement with those obtained by qRT-PCR analysis (Figure 7C).
Significantly, genes involved in the regulation of fat metabolism
were also altered. Some genes involved in fatty acid catabolism
were upregulated in WAT, as assessed by both microarray and
qRT-PCR (Figure 7B and 7D and Table S3). These include
patatin-like phospholipase domain containing 3 (Pnpla3), a
triacylglycerol lipase, and acyl CoA synthetase (Acss2). Such
changes may help explain the lower fat mass and higher RER of
Fto
I367F mice. Interestingly, Pnpla3 has been associated with fatty
liver disease in humans [30]: however the liver triglyceride
concentration was unchanged in Fto
I367F mice (Figure S7G). Genes
involved in fatty acid synthesis were also upregulated, including
fatty acid synthase (Fasn), pyruvate carboxylase (Pcx), monoacyl-
glycerol O-acyltransferase (Mogat1, Mogat2), and acetyl-Coenzyme
A carboxylase (Acaca, Acacb). Given the reduced amount of WAT
in Fto
I367F mice, upregulation of genes involved in fat synthesis
may be a secondary adaptation that attempts to compensate for
the lower fat levels.
In muscle, fatty acid synthase (Fasn) was strongly upregulated in
16- week old homozygous Fto
I367F mice, being 10-fold higher by
microarray and 3.5-fold higher by qRT-PCR (Figure 7E). Some
genes involved in carbohydrate catabolism were also slightly
upregulated, including glucose-6-phosphate dehydrogenase (G6pd),
pyruvate dehydrogenase kinase (Pdk4) and insulin receptor
substrate 1 (Irs-1; Figure 7E, Table S4). These changes are
consistent with the idea that carbohydrate metabolism may be
increased in muscle of Fto
I367F mice.
Genes associated with endoplasmic reticulum (ER) stress and
the unfolded protein response (UPR) also showed a small increase
($1.3-fold) in expression in the liver of 16-week old homozygous
Fto
I367F mice, as assessed by microarray studies (Figure S9). Such
changes are too small to be measured by qRT-PCR. There were
no major changes in metabolic genes, consistent with the lack of a
change in plasma glucose concentrations at this time point.
qRT-PCR analysis of the key hypothalamic neuropeptides Agrp,
Npy and Pomc revealed no significant changes in relative mRNA
expression between Fto
I367F and wild-type mice in the fasted state
(Figure S10). However, a significant reduction in Npy expression
was observed in Fto
I367F mice in the free-fed state (Figure S10).
Discussion
We have identified a point mutation in the mouse Fto gene at a
highly conserved residue within a novel C-terminal domain that is
largely composed of a-helices and is involved in FTO dimerisa-
tion. Like the wild-type protein, the FTO
I367F protein localises to
the nucleus. Male Fto
I367F mice exhibit a lean phenotype with
reduced body weight and fat mass, despite normal physical
activity. This appears to result from an increase in whole body
A Mutation in FTO Causes a Lean Phenotype
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differences are often observed in mouse models of obesity and
diabetes and are thought to be due to a protective effect of female
sex hormones [31,32]. Although most human studies have not
reported any gender differences, a recent study suggested that the
effect of FTO on BMI in a Slavic population is restricted to males
and postmenopausal females [33].
Properties of FTO
We found that in vitro wild-type mFTO dimerises, probably via
its novel helical C-terminal domain, and that it can exist in both
monomeric and dimeric forms. Substitution of isoleucine-367 for
phenylalanine resulted in insoluble protein when expressed in E.
coli and a substantially reduced level of expression in mammalian
cells. However alanine substitution at residue 367 resulted in
Figure 6. Fto
I367F increases sympathetic activity. (A–C) Urinary catecholamines norepinephrine (A), dopamine (B) and epinephrine (C) at 10 and
20 weeks (10W; 20W) in heterozygous (I/F; grey bars) and homozgygous (F/F; white bars) Fto
I367F mice compared to wild-type controls (I/I; black bars).
10 weeks: I/I, n=13; I/F, n=10; F/F=10. 20 weeks: I/I, n=14; I/F, n=14; F/F, n=15. (D–F) Gene expression in skeletal muscle (D), WAT (E) and BAT (F)
expressed relative to GAPDH. Abbreviations not used previously: adrenergic beta-1 receptor (Adrb1), adrenergic beta-2 receptor (Adrb2), uncoupling
protein 1 (Ucp1). Data are expressed as mean6SEM. *, P,0.05 (Student’s t-test) for differences between Fto
I367F and wild-type mice.
doi:10.1371/journal.pgen.1000599.g006
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I367F gene expression analyses. (A) Overlap between statistically changing genes with$1.5 fold change in WAT, liver and skeletal
muscle of homozygous Fto
I367F mice. (B) Hierarchical clustering of 121 differentially expressed immune genes and 22 fatty acid metabolism genes.
Each row represents an individual animal and each column a single gene. Red-blue color code represents the relative intensity of the expression
signal, with red indicating high expression and blue low expression. (C–E) Gene expression levels, relative to GAPDH, measured by q-RT-PCR for
immune genes in WAT (C), and genes involved in fatty acid metabolism (D), or metabolism (E) in skeletal muscle. Black bars: wild-type mice (I/I;
n=10). Grey bars: heterozygous mice (I/F; n=9). White bars: homozygous (F/F; n=11). Abbreviations not used previously: Acsl5, acyl-CoA synthetase
long-chain family member 5; Acaa2, acetyl-Coenzyme A acyltransferase 2. Data are expressed as mean6SEM. *, P,0.05. **, P,0.01. ***, P,0.001
(Student’s t-test) for differences between Fto
I367F and wild-type mice.
doi:10.1371/journal.pgen.1000599.g007
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I367A has a similar secondary structure to
mFTO, although the fraction of dimeric protein was significantly
reduced and its catalytic activity was decreased.
Our results suggest the mFTO
I367F allele may exert a
heterozygous hypomorphic effect. Heterozygous Fto knockout
mice resemble wild-type mice, indicating the presumed FTO
reduction is not sufficient to elicit a phenotype (haploinsufficiency).
However, because heterozygous and homozygous Fto
I367F mice
exhibited a similar phenotype, it appears that an mFTO
I367F
protein can exert a dominant negative effect on mFTO function,
possibly by disrupting the wild-type mFTO subunit by formation
of a heterodimeric protein complex (i.e. an antimorphic allele).
ER stress genes were among those genes whose expression was
increased in the liver of 16-week old homozygous Fto
I367F mice. It
is possible these gene changes are secondary to impaired folding of
FTO
I367F, as suggested by the fact that the recombinant protein
aggregated in solution. However, qRT-PCR analysis did not reach
statistical significance suggesting FTO
I367F may only be initiating a
mild unfolded protein response.
Mechanism of Action of FTO
Most sick animals will tend to lose weight. However, the fact
that food intake and physical activity of Fto
I367F mice are normal
indicates their lean phenotype is unlikely to be a consequence of
illness or general malaise. In contrast, the I367F mutation
produced a marked increase in whole body metabolism, with
both O2 consumption and CO2 production being stimulated. This
argues that the changes in fat mass are produced by differences in
metabolism. Interestingly, RER increased from 0.87 to 0.9 during
the dark period (when the mice are active). This is consistent with
a switch from fat metabolism (RER=0.7) towards protein
(RER=0.9) and/or carbohydrate (RER=1.0) metabolism, which
most likely reflects the fact that mutant animals have smaller fat
depots.
We found some evidence for alterations in catecholamines and
sympathetic nervous system activity that are consistent with an
increased metabolic rate. The increased glucagon level of Fto
I367F
mice further supports an increased sympathetic tone (as this
stimulates glucagon secretion).
On either a standard or a high-fat diet, Fto
I367F mice exhibited
reduced fat mass, unchanged food intake, and increased serum
leptin, glucose, glucagon and lipid serum levels compared with
wild-type mice. However the lean mass of Fto
I367F mice was
greater than that of wild-type on a high-fat diet, whereas no
differences were observed on a normal diet. Consequently, overall
weight was not significantly different between Fto
I367F and wild-
type mice on a high fat diet. It is striking that that despite the
reduction in protein and carbohydrate, the lean mass of Fto
I367F
mice increases on the high-fat diet. All mice on the high-fat diet
have a higher fat mass than on a standard diet, although the
Fto
I367F mutation affords some protection against increased
adiposity.
Finally, we did not observe any differences in metabolic rate
between genotypes given a high-fat diet, suggesting that the
increased fat metabolism (particularly in wild-type mice) masks the
differences observed on a standard diet. The RERs on the high-fat
diet were all reduced, as expected due to the relatively higher fat
metabolism. However, the active (night) phase RER was
significantly higher in Fto
I367F than wild-type mice fed a high-fat
(or standard) diet, indicating a switch in substrate use towards
carbohydrate.
How the Fto
I367F mutation enhances metabolism requires
further study. Nevertheless, it is interesting that other Fe(II) and
2OG oxygenases are involved in fat metabolism [34]. Given that
the amount of adipose tissue is significantly reduced in Fto
I367F
mice, the increased expression of genes involved in lipid
metabolism pathways can be interpreted to suggest that fatty acid
catabolism dominates in WAT and is the primary cause of reduced
WAT levels, and that changes in levels of anabolic genes are a
secondary effect. Overall, enhanced fat metabolism in WAT may
not contribute to RER as much as in wildtype animals because of
the reduced fat mass in Fto
I367F mice.
Gene expression analysis showed a slight increase in carbohy-
drate metabolic genes in muscle of Fto
I367F mice. This might
contribute to the phenotype of these mice as they exhibit a higher
metabolic rate and higher RER. It is also possible that these
changes are secondary to changes in substrate supply to muscle,
produced by changes in nutrient storage in WAT and liver. The
elevation of fatty acid synthase (Fasn) levels suggests that fat
synthesis could be enhanced in muscle. However, there was no
obvious increase in fat storage in this tissue so this change may be a
secondary consequence of a decreased supply of fatty acids to
muscle resulting from the lean phenotype.
A reduction in expression of genes involved in the inflammatory
response is consistent with the lean phenotype of the Fto
I367F mice
and may reflect concomitant reduction of macrophages residing in
WAT. Previous reports have shown inflammation has an
important role in obesity and that a lean phenotype results in
decreased expression of inflammatory markers [27,28,29].
We found a significant reduction in Npy expression in Fto
I367F
mice in the free-fed state (compared to controls). However, we did
not observe any significant effect on food intake. Knockout of
FTO had no effect on fed levels of Npy expression but produced a
small reduction in fasting Npy and Pomc levels [24].
Does Loss or Gain of FTO Function Cause Obesity?
Our data suggest that the I367F mutation leads to a reduction in
FTO activity. The mutant protein is expressed at lower levels than
wild-type in E. coli, mammalian cell lines, and in tissues isolated
from mutant mice. This reduction in FTO protein levels is
expected to result in a decrease in total FTO activity.
Furthermore, although the activity of mFTO
I367F could not be
measured that of mFTO
1367A was reduced.
The Fto
I367F mouse shares several features with a mouse in
which the Fto gene has been knocked out [24], which provides
additional support for the idea that the Fto
I367F mutation causes a
(partial) loss of function. Thus, in the homozygous state, both types
of mice weigh less than wild-type, have a reduced fat mass, exhibit
an increased metabolic rate and increased sympathetic nervous
system activity and have a stronger phenotype in male than female
mice.
Collectively, these data suggest that FTO is involved in fat
accumulation and that reduction in the activity of its gene product
accounts for the lean phenotype of our mutant mice.
Differences between Fto
I367F and Fto Knockout Mice
There are, however, significant differences between Fto
I367F
mice and the Fto knockout mouse [24]. This is presumably because
the latter results in a null allele, whereas the mFTO
I367F protein
may retain some functional activity, as suggested by the lowered
activity of mFTO
I367A.
The Fto knockout mouse exhibits no significant phenotype in the
heterozygous state [24], whereas heterozygous Fto
I367F mice
resemble their homozygous littermates. As described above, this
most probably results from a dominant negative effect of the I367F
mutation. Thus, inhibition of FTO dimerisation may represent a
novel strategy for inhibition of FTO activity. We confine our
discussion here to a comparison of homozygous animals.
A Mutation in FTO Causes a Lean Phenotype
PLoS Genetics | www.plosgenetics.org 11 August 2009 | Volume 5 | Issue 8 | e1000599The divergence of weight between knockout and wild-type mice
has an early onset being apparent from day 2 after birth, and by 6
weeks of age homozygous mice weigh 30–40% less than controls.
In contrast, the weight of homozygous Fto
I367F mice only diverges
after 12 weeks and at its maximum (24 weeks) is only 10% less than
wild-type. This smaller weight difference is closer to that observed
in humans carrying different FTO SNPs, where the mean
difference between at-risk and low-risk alleles is 3 kg for an
average adult body weight of 90 kg - or around 3.4% [1].
Fto knockout mice are smaller than wild-type (on average, males
are 1.5 cm shorter) [24]. In contrast, Fto
I367F mice showed no
difference in body length, which is consistent with the lack of
association of human FTO SNPs with height [1,21].
Fat mass was reduced by 60% and 23% in homozygous male
and female Fto knockout mice, respectively. In contrast, we only
observed a phenotype in males and the reduction in fat mass was
much less, between 16–18%. This is closer to the difference in
body fat of 14% found between humans with at-risk and low-risk
FTO variants [1].
There are several other differences between Fto
I367F and Fto
knockout mice. In particular, the latter showed a postnatal
increase in mortality suggesting they are less healthy. They also
exhibited relative hyperphagia and decreased spontaneous loco-
motor activity, which we did not detect in Fto
I367F mice.
These data reveal that the phenotype of Fto
I367F mice more
closely resembles that of human FTO variants than the knockout
mice, and suggests that the low-risk allele does not result in a total
knockout of FTO function in humans. The Fto
I367F mouse
provides a more physiologically relevant model for studying the
effects of human FTO variants than a complete gene knockout,
where the phenotype is more extreme.
Relation to Human FTO
Human studies suggest that FTO SNPs are not associated with
differences in physical activity, as found for Fto
I367F mice [20].
There is strong evidence for increased food intake in humans with
the ‘at-risk allele’. This was not observed in Fto
I367F mice although
homozygotes showed a trend to towards reduced food intake on
both standard and high-fat diets. Unlike humans with FTO gene
variants, we observed no differences in homozygous and
heterozygous mice. However, this is not unexpected as we have
shown that our mutation affects FTO dimerisation, which may
lead to dominant negative effects: it is unlikely this occurs with an
intronic SNP, which presumably exerts a gene dosage effect on
protein levels.
Conclusions
Our data provide functional evidence that FTO is a causal gene
underlying the association of SNPs within intron 1 of FTO with
obesity. They further suggest that the ‘at-risk’ allele may lead to
enhanced FTO function - or conversely that the low risk allele may
lead to reduced FTO function.
The Fto
I367F model shows that mutations in this gene are
consistent with viable metabolic effects and provides a physiolog-
ically more relevant model for further study than does the
knockout mutation where the phenotype is more extreme.
Our results cannot exclude the possibility that the intronic SNP
found in humans may have an additional regulatory role on other
genes. Nevertheless, because a missense point mutation is unlikely
to affect the expression of adjacent genes, the phenotype of our
mice provides strong support for the idea that FTO function does
regulate body weight and further reinforces the evidence from the
mouse knockout. By showing that FTO affects whole body
metabolism, they provide the basis for further studies designed to
elucidate the molecular mechanism of how FTO influences body
weight. The observation that impaired FTO function results in a
lean phenotype also suggests that inhibition of FTO may be of
therapeutic interest in relation to morbid obesity.
Materials and Methods
ENU Mutation in Exon 6
The Harwell ENU-DNA archive (http://www.har.mrc.ac.uk/
services/dna_archive/) was screened by denaturing high perfor-
mance liquid chromatography (dHPLC) using a Transgenomic
WAVE system [25,35]. Coding sequence from the 9 Fto exons,
including flanking (approximately 70 bp) splice sites, was tested in
DNA derived from 6,624 mutagenised animals giving a total of
approximately 10.29 Mbp screened (see Text S1 for primer
sequences). Six ENU induced point mutations (2 missense, 3
intronic (non-splice site), 1 silent) were found. We selected an exon
6 missense mutation (I367F) for further work. Fto exon 6 was
amplified with the following primers: FTOex6F 59 ATGTA-
CAGCTGGAAGAGTGC-39 and FTOex6R 59-
TCCCCTCTGACTAGGATCTC-39 using Ampli Taq Gold
(Applied Biosystems). The mouse (C57BL/6J6C3H/HeH F1)
was rederived by in vitro fertilization from frozen sperm using
C3H/HeH eggs. Progeny were backcrossed for two generations to
C3H/HeH and intercrossed to produce mice heterozygous and
homozygous for the mutation.
Sequence Analysis
PCR amplification products were purified using a QIAquick
PCR purification kit (Qiagen). Sequencing reactions were
performed by GATC Biotech (Jakob-Stadler-Platz 778467 Kon-
stanz, Germany) and analyzed using Vector NTI advance 10-
ContigExpress (Invitrogen).
Sequence Alignment
FTO genomic, transcript and peptide sequences were exported
from Ensembl (http://www.ensembl.org/index.html). Sequence
alignment was performed using NTI advance 10-AlignX software
(Invitrogen).
Mutant Construct Production
cDNA encoding hFTO was synthesised by Geneart and cloned
into the pET-28a(+) vector to generate a His-tagged fusion
protein. The hFTO construct used was produced by deletion of
the thrombin cleavage region separating the His-tag from the
protein sequence, using the QuikChange Site-Directed Mutagen-
esis Kit (Stratagene), and confirmed by DNA sequencing. This
construct was used to prepare the hFTO 332–505 truncation
(ChFTO). The mFTO 329–502 truncation (CmFTO), C-terminal
truncations mFTO 1–408, mFTO 1–387 and mFTO 1–329, and
point mutant I367F mFTO and I367A mFTO constructs were
prepared in a similar manner from the wild-type mFTO construct.
Further details are provided in the Text S1.
Protein Expression and Purification
Proteins were prepared as previously reported for full length
mFTO [8].
Analytical Gel Filtration Analyses
Protein (250 mg) was loaded onto a Tricorn 10/300 GL column
packed with Superdex 75 (CmFTO and CmFTO
I367A)o r
Superdex 200 (mFTO and mFTO
I367A). Chromatographic
separation was achieved using one column volume of running
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pH 7.5. The UV trace of the eluted volume was monitored.
Protein standards used to create calibration curves were analysed
by the same method. For CmFTO the masses obtained were
23.2 kDa and 38.2 kDa, consistent with the presence of
monomeric and dimeric species (calculated masses of 21.6 and
43 kDa, respectively). CmFTO
I367A elutes at a volume corre-
sponding to 27.8 kDa.
Circular Dichroism Analyses
Protein (0.25 mg/ml) samples were analysed in 50 mM KCl,
20 mM K2PO4, pH 7.0, on an Applied Photophysics Chirascan
machine, with 1 mm pathlength quartz cuvettes. Measurements
were taken at 0.5 nm intervals between 180 and 260 nm at 4uC.
Spectral fitting to determine relative contributions of secondary
structure elements was performed using a CDNN deconvolution
program (Chirascan).
Non–Denaturing Mass Spectrometric Analyses
Protein samples were exchanged into 15 mM ammonium
acetate, pH 7.5. ESI-MS was carried out on a Waters Micromass
Q-ToF spectrometer and an Advion Biosciences NanoMate HD
Robot chip-based nano-electrospray device. 10 mM protein
samples were sprayed from 15 mM NH4OAc (pH 7.5) at a chip
nozzle voltage of 1.66 kV and cone voltage of 80 V. Samples were
also run on a Waters Synapt HDMS, Advion Biosciences
NanoMate HD Robot chip-based nano-electrospray device.
15 mM protein samples were sprayed from 15 mM NH4OAc
(pH 7.5) at a chip nozzle voltage of 1.7–1.8 kV, a gas pressure of
0.25 psi and cone voltage of 80 V.
2OG Decarboxylation Assays
Decarboxylation assays of [1-
14C]-labelled 2OG were carried
out as reported [36], and incubated (37uC for 10 minutes). Assays
were carried out with an 18mer methylated oligonucleotide
substrate of sequence 59-GCXAGGTCCCGTAGTGCG-39,
where X is 3-methylthymine, which was synthesised by ATDBio
Ltd. (University of Southampton, UK). Assay mixes contained
4 mM enzyme, 100 mM substrate, 4 mM ascorbic acid, 300 mM
2OG (4% [1-
14C]-2OG), 0.3 mg/ml catalase, 1 mM DTT and
25 mM FeSO4.7H2O, made to 100 ml with 50 mM Tris pH 7.5.
Constructs for Fluorescent FTO Fusion Proteins
An N-Terminally labelled YFP-Fto fusion construct was
generated as described [8]. The I367F variant was created from
the wild-type construct using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene) and confirmed by DNA sequencing.
The primers used were (bold codons indicate the site of mutation):
mFTOI367F fwd: 59- AAA CAA GGA GAG GAA TTC CAT
AAT GAG GTG GAG -39mFTOI367F rev: 59- CTC CAC CTC
ATT ATG GAA TTC CTC TCC TTG TTT-39. Cell culture
and confocal microscopy are described in Text S1.
The HA-Fto chimera was generated by fusing an HA coding
sequence to the N-terminus of FTO by PCR. The amplified PCR
product was cloned into the pGEM-T Easy vector (Promega),
sequenced, and then recloned into the pcDNA3 vector (Invitro-
gen). The I367F variant was created from the wildtype construct
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene).
Protein Extraction and Immunoblotting
Western blots were performed on 40 mg of total proteins using a
rabbit anti recombinant mFTO antibody. Detection was per-
formed using ultrasensitive horseradish Enhanced Chemilumines-
cence Plus (ECL plus; Amersham). Cos-7 cells expressing HA-
FTO or HA-FTOI367F, were lysed with RIPA buffer (containing
1% NP40, 0.5% DOC and 0.1% SDA detergents) and proteins
separated by SDS-PAGE. Blots were probed with an anti-HA
antibody (Roche) and with an antibody to the TATA-binding
protein (Abcam) as a loading control for nuclear proteins.
Animal Experiments
All animal studies were carried out using guidelines issued by
the Medical Research Council in ’Responsibility in the Use of
Animals for Medical Research’ (July 1993). Mice were kept in
accordance with UK Home Office welfare guidelines and project
license restrictions under controlled light (12 hr light and 12 hr
dark cycle, dark 7 pm-7 am), temperature (2162uC) and humidity
(55%610%) conditions. They had free access to water (25 ppm
chlorine) and were fed ad libitum on a commercial diet (SDS Rat
and Mouse No.3 Breeding diet (RM3)) containing 11.5 kcal% fat,
23.93 kcal% protein and 61.57 kcal% carbohydrate. Alternatively,
mice were maintained on a high-fat diet (D12451, Research Diets,
New Brunswick, NJ, USA) containing 45 kcal% fat, 20 kcal%
protein and 35 kcal% carbohydrate. Phenotyping tests were
performed according to EMPReSS (European Phenotyping
Resource for Standardised Screens from EUMORPHIA) stan-
dardized protocols as described at (http://empress.har.mrc.ac.uk).
Body Mass and Composition
Body mass was measured each week on scales calibrated to
0.01 g. Analysis of body composition was performed by DEXA
using the Lunar PIXImus Mouse Densitometer (Wipro GE
Healthcare, Madison, WI).
Measurement of Food Consumption, Blood, Serum, and
Urinary Parameters
At 10 and 20 weeks of age mice were placed in metabolic
Techniplast cages with free access to water and food. Food
consumption was measured by weighing. Urine was collected after
24 hours and urinary catecholamines measured using a 3-CAT
Epinephrine, Norepinephrine, Dopamine ELISA (Demeditec)
according to the manufacturer’s instructions. Creatinine was used
to standardize between urine samples. Plasma leptin insulin,
adiponectin and glucagon levels were measured using a mouse
endocrine Lincoplex kit (Linco research, Missouri, USA) and a
Bio-Plex 200 system (Bio-Rad, Hemel Hempstead, UK), according
to the manufacturer’s instructions. At 24 weeks of age, fasted mice
were anaesthetized, killed by exsanguination and blood collected
by cardiac puncture. Plasma concentrations of glucose, triglycer-
ides, total cholesterol, HDL cholesterol and LDL cholesterol and
urine creatinine were measured on an AU400 (Olympus UK), as
described [37].
Metabolic Rate and Activity Measurements
Metabolic rate was measured at 18 weeks of age using indirect
calorimetry (Oxymax; Columbus Instruments) to determine
oxygen consumption, carbon dioxide production, respiratory
exchange ratio (RER) and heat production. Physical activity was
assessed using a Threshold load cell system (Med Associates, VT,
USA) over 22 hours and analysed with Threshold Summary,
Version 3.0 for upper and lower threshold crossings.
Gene Expression Profiling
Total ribonucleic acid (RNA) from WAT, skeletal muscle and
liver was labelled and hybridised to Affymetrix Mouse GeneST
arrays. Arrays were analysed using GeneSpring GX10, GenMAPP
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compliant and has been submitted to ArrayExpress under
accession number E-MEXP-2201. Further details of the micro-
array methodology and SYBR-Green/Taqman (Table S5) PCR
assays are described in the Text S1.
Statistics
Statistical analyses were performed with a Student’s t-test for
independent samples. Correlation coefficients were obtained by
the Pearson method using GraphPad Prism version 5.00 for
Windows, GraphPad Software, San Diego California USA, www.
graphpad.com. Data are expressed as mean6SEM, and P,0.05
was considered as statistically significant. For microarray studies,
differentially expressed genes were identified (after RMA normal-
ization) using an unpaired t-test with a cut-off of P#0.05. A$1.5-
fold change difference between wildtype and Fto
I367F mice was
taken to indicate expression changes between genotypes.
Additional detail on materials and methods is given in Text S1.
Supporting Information
Figure S1 Non-denaturing mass spectrometric analysis of
CmFTO. Peak A corresponds to the predicted mass of the C-
terminal domain of mFTO, CmFTO (21522 Da). Peak B likely
results from a-N-gluconylation of the N-terminal His-tag of
CmFTO, creating a +178 Da adduct (see Figure S2).
Found at: doi:10.1371/journal.pgen.1000599.s001 (0.58 MB TIF)
Figure S2 Scheme showing the likely modification of the N-
terminal His-tag of the CmFTO protein by a-N-gluconylation of
an N-terminal amino group, creating a +178 Da adduct [3].
Found at: doi:10.1371/journal.pgen.1000599.s002 (0.46 MB TIF)
Figure S3 Non-denaturing electrospray ionisation mass spec-
trometry analyses carried out on a Waters Synapt
TM HDMS
TM,
showing the oligomeric composition of (i) I367A mFTO, (ii)
mFTO and (iii) hFTO.
Found at: doi:10.1371/journal.pgen.1000599.s003 (0.60 MB TIF)
Figure S4 Secondary structure predictions showing relative
proportions of secondary structure elements present in CmFTO
(left) and mFTO (right), obtained through spectral fitting of
circular dichroism spectra (Figure 2D) using the program CDNN
(Chirascan). A greater proportion of a-helix is identified in the C-
terminus of mFTO (CmFTO) than for the full length mFTO.
Proportions obtained for the analogous proteins for the I367A
variants are very similar (data not shown).
Found at: doi:10.1371/journal.pgen.1000599.s004 (0.31 MB TIF)
Figure S5 Difference circular dichroism spectra, identifying the
increased proportion of a-helical content in the C-terminal domain
relative to the wild-type FTO proteins, and indicating overall
structural similarity between the wild type and I367A variants:
mFTO-CmFTO (blue), I367A mFTO-I367A CmFTO (red),
hFTO-ChFTO (light blue), mFTO-I367A mFTO (green),
CmFTO-I367A CmFTO (black).
Found at: doi:10.1371/journal.pgen.1000599.s005 (0.39 MB TIF)
Figure S6 Circular dichroism spectra showing the secondary
structures of hFTO (red), and ChFTO (blue) at 0.25 mM, 4uC.
Found at: doi:10.1371/journal.pgen.1000599.s006 (0.33 MB TIF)
Figure S7 (A,B) Intraperitoneal glucose tolerance test (A) at 12
weeks following overnight fasting (B) at 16 weeks following
overnight fasting. Heterozgyous (I/F, n=23), homozygous (F/F,
n=18) and wildtype littermate (I/I, n=22). (C) Circulating
overnight fast plasma leptin level at 24 weeks. Heterozgyous (I/F,
n=26), homozygous (F/F, n=19) and wildtype littermate (I/I,
n=28). (D) Circulating overnight fast plasma leptin level expressed
as a function of percentage of body fat at 24 weeks. Heterozgyous
(I/F, n=25), homozygous (F/F, n=19) and wildtype littermate (I/
I, n=18). (E) Circulating overnight fast plasma insulin level at 24
weeks. Heterozgyous (I/F, n=26), homozygous (F/F, n=19) and
wildtype littermate (I/I, n=28). (F) Circulating overnight fast
plasma adiponectin level at 24 weeks Heterozgyous (I/F, n=26),
homozygous (F/F, n=10) and wildtype littermate (I/I, n=14). (G)
Liver triglyceride concentration at 24 weeks. Heterozgyous (I/F,
n=8), homozygous (F/F, n=7) and wildtype littermate (I/I,
n=8). Data are expressed as mean6SEM, Statistical analysis was
carried out using the Student’s t-test for differences between
Fto
I367F heterozygous or homozygous mice and wild-type litter-
mates.
Found at: doi:10.1371/journal.pgen.1000599.s007 (0.80 MB TIF)
Figure S8 A-C Body Mass (A) fat mass (B) and lean body mass
(C) of 24-week old male heterozygous (n=20), homozygous
(n=15) and wildtype (n=9) on high fat diet. (D) Food Intake over
24 hours (10 wk I/I n=14, I/F n=22, F/F n=9, 20 wk I/I
n=12, I/F n=22, F/F n=9) on high fat diet. E-G Circulating
overnight fasting plasma insulin (E), leptin (F) and glucagon (G)
level at 8 and 24 weeks. Heterozgyous (I/F, n=20), homozygous
(F/F, n=9) and wildtype littermate (I/I, n=12). (H) Glucose and
lipid serum levels were measured after overnight fasting at 24-
weeks of age. WT (I/I; n=11), Heterozygous (I/F; n=18),
Homozygous (F/F; n=9). I-K Oxygen Consumption (I) and
carbon dioxide production (J) and calculated respiratory exchange
ratio (RER; K) during the light and dark period for 18-week old
males on standard diet (heterozygous (I/F; n=30) and homozy-
gous (F/F; n=15) and Fto
I367F mice wild-type littermates (I/I;
n=26) and high fat diet (heterozygous (I/F; n=23) and
homozygous (F/F; n=9) Fto
I367F mice wild-type littermates (I/I;
n=12). L-M Oxygen Consumption (L) and carbon dioxide
production (M) over a 22-hr period for 18- week old male
heterozygous (I/F; n=23) and homozygous (F/F; n=9) Fto
I367F
mice and wild-type littermates (I/I; n=12) on high fat diet. Data
are expressed as mean6SEM, Statistical analysis was carried out
using the Student’s t-test (* P,0.05, **P,0.01, *** P,0.001) for
differences between Fto
I367F heterozygous or homozygous mice
and wild-type littermates.
Found at: doi:10.1371/journal.pgen.1000599.s008 (0.11 MB PDF)
Figure S9 Endoplasmic Reticulum Stress pathway in homozy-
gous Fto
I367F mice liver microarray. Upregulated genes are marked
in red and genes showing no change in expression are shown in
grey (Downloaded from Ingenuity).
Found at: doi:10.1371/journal.pgen.1000599.s009 (3.25 MB TIF)
Figure S10 Gene expression in hypothalamus of Agrp, Npy, and
Pomc in Fto
I367F expressed relative to GAPDH. Free fed
heterozgyous (I/F, n=6), homozygous (F/F, n=7) and wildtype
littermates (I/I, n=7). Fasted heterozgyous (I/F, n=8), homozy-
gous (F/F, n=8) and wildtype littermate (I/I, n=8). Data are
expressed as mean6SEM, Statistical analysis was carried out using
the Student’s t-test for differences between Fto
I367F heterozygous or
homozygous mice and wild-type littermates. *, P,0.05.
Found at: doi:10.1371/journal.pgen.1000599.s010 (0.57 MB TIF)
Table S1 Metabolic parameters in female Fto
I367F mice. Values
are mean6SEM. Numbers shown in brackets represent n number
for each parameter. No statistically significant differences were
observed between female wildtype littermates (I/I) and heterozy-
gous (I/F) mice and homozygous (F/F) Fto
I367F mice.
Found at: doi:10.1371/journal.pgen.1000599.s011 (0.05 MB PDF)
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Fto
I367F white adipose tissue.
Found at: doi:10.1371/journal.pgen.1000599.s012 (0.07 MB PDF)
Table S3 Fatty acid metabolism genes statistically altered$1.5
fold in 16 week Fto
I367F white adipose tissue.
Found at: doi:10.1371/journal.pgen.1000599.s013 (0.02 MB PDF)
Table S4 Metabolism genes statistically altered$1.5 fold in 16
week Fto
I367F liver.
Found at: doi:10.1371/journal.pgen.1000599.s014 (0.01 MB PDF)
Table S5 Taqman Gene Expression Assay, probe Assay ID for
qRT-PCR.
Found at: doi:10.1371/journal.pgen.1000599.s015 (0.01 MB PDF)
Text S1 Supplemental data.
Found at: doi:10.1371/journal.pgen.1000599.s016 (0.06 MB
DOC)
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